Fabiana Gregucci1, Alba Fiorentino2, Stefanie Corradini3, Vanessa Figlia2, Rosario Mazzola2, Francesco Ricchetti2, Ruggero Ruggieri2, Filippo Alongi2,4. 1. Department of Radiation Oncology, IRCCS, Sacro Cuore Don Calabria Hospital, Via don A. Sempreboni 5, 37024, Negrar, Verona, Italy. fabianagregucci@gmail.com. 2. Department of Radiation Oncology, IRCCS, Sacro Cuore Don Calabria Hospital, Via don A. Sempreboni 5, 37024, Negrar, Verona, Italy. 3. Department of Radiation Oncology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany. 4. University of Brescia, Piazza del Mercato 15, 25121, Brescia, Italy.
Abstract
AIM: The aim of this study was to analyze the feasibility and clinical results of linear accelerator (linac-)based stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (SFRT) with flattening filter-free (FFF) volumetric modulated arc therapy (VMAT) in elderly patients affected by brain metastases (BMs). PATIENTS AND METHODS: Patients selected for the present analysis were ≥65 years old with a life expectancy of >3 months, a controlled or synchronous primary tumor, and <10 BMs with a diameter <3 cm. All patients were treated with FFF linac-based SRS/SFRT. The prescribed total dose (15-30 Gy/1-5 fractions) was based on BM size and proximity to organs at risk (OAR). Toxicity was assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.0. MedCalc v18.2 (MedCalc Software, Ostend, Belgium) was used for statistical analysis. RESULTS: From April 2014 to December 2017, 40 elderly patients with 110 BMs were treated by FFF linac-based SRS/SFRT. With a median follow-up of 28 months (range 6-50 months), median and 1‑year overall survival were 9 months and 39%, respectively; median intracranial progression-free survival was 6 months. At the time of the analysis, local control was reported in 109/110 BMs (99.1%): 12 BMs had a complete response; 51 a partial response; 46 showed stable disease. One BM (0.9%) progressed after 2 months. BM volume (<1 cc) and higher SRS/SFRT dose correlated to treatment response (p = 0.01 and p = 0.0017, respectively). No adverse events higher than grade 2 were observed. CONCLUSION: The present findings highlight the feasibility, safety, and effectiveness of FFF linac-based SRS/SFRT in elderly patients with BMs.
AIM: The aim of this study was to analyze the feasibility and clinical results of linear accelerator (linac-)based stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (SFRT) with flattening filter-free (FFF) volumetric modulated arc therapy (VMAT) in elderly patients affected by brain metastases (BMs). PATIENTS AND METHODS: Patients selected for the present analysis were ≥65 years old with a life expectancy of >3 months, a controlled or synchronous primary tumor, and <10 BMs with a diameter <3 cm. All patients were treated with FFF linac-based SRS/SFRT. The prescribed total dose (15-30 Gy/1-5 fractions) was based on BM size and proximity to organs at risk (OAR). Toxicity was assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.0. MedCalc v18.2 (MedCalc Software, Ostend, Belgium) was used for statistical analysis. RESULTS: From April 2014 to December 2017, 40 elderly patients with 110 BMs were treated by FFF linac-based SRS/SFRT. With a median follow-up of 28 months (range 6-50 months), median and 1‑year overall survival were 9 months and 39%, respectively; median intracranial progression-free survival was 6 months. At the time of the analysis, local control was reported in 109/110 BMs (99.1%): 12 BMs had a complete response; 51 a partial response; 46 showed stable disease. One BM (0.9%) progressed after 2 months. BM volume (<1 cc) and higher SRS/SFRT dose correlated to treatment response (p = 0.01 and p = 0.0017, respectively). No adverse events higher than grade 2 were observed. CONCLUSION: The present findings highlight the feasibility, safety, and effectiveness of FFF linac-based SRS/SFRT in elderly patients with BMs.
Entities:
Keywords:
Aged; Organs at risk; Quality of life; Survival; Toxicity
Authors: P Mehta; S Janssen; F B Fahlbusch; S M Schmid; J Gebauer; F Cremers; C Ziemann; M Tartz; D Rades Journal: BMC Cancer Date: 2020-06-30 Impact factor: 4.430
Authors: Rami A El Shafie; Eric Tonndorf-Martini; Daniela Schmitt; Aylin Celik; Dorothea Weber; Kristin Lang; Laila König; Simon Höne; Tobias Forster; Bastian von Nettelbladt; Sebastian Adeberg; Jürgen Debus; Stefan Rieken; Denise Bernhardt Journal: Front Oncol Date: 2020-05-08 Impact factor: 6.244
Authors: Edward T Cullom; Yuqing Xia; Kai-Cheng Chuang; Zachary W Gude; Yana Zlateva; Justus D Adamson; William M Giles Journal: J Appl Clin Med Phys Date: 2021-06-24 Impact factor: 2.102
Authors: Fabiana Gregucci; Ilaria Bonaparte; Alessia Surgo; Morena Caliandro; Roberta Carbonara; Maria Paola Ciliberti; Alberto Aga; Francesco Berloco; Marina De Masi; Christian De Pascali; Federica Fragnoli; Chiara Indellicati; Rosalinda Parabita; Giuseppe Sanfrancesco; Luciana Branà; Annarita Ciocia; Domenico Curci; Pietro Guida; Alba Fiorentino Journal: J Pers Med Date: 2021-12-12